Spectru Health

Spectrum Physician's Orders Health EPOETIN ALFA (PROCRIT/RETACRIT) -ADULT, OUTPATIENT, INFUSION CENTER Page 1 to 2

Patient Name				
DOB				
MRN				
Physician				
FIN				

Defaults for orders not otherwise specified below:

- Interval: Every 7 days
- Interval: Every 7 days x 8 treatments
- Interval: Every _____ days
- Interval: Once

Duration:

- Until date: _
- 1 year

of Treatments

Anticipated Infusion Date	ICD 10 Code with Desc		cription	
Height(cn	n) Weight	(kg) Allergies_		
Site of Service				
SH Gerber	🗆 SH Lemme	n Holton (GR)	SH Pennock	SH United Memorial
□ SH Helen DeVos (GR)	SH Ludingt	on	SH Reed City	SH Zeeland
Provider Specialty	-			
Allergy/Immunology	Infectious D	Disease	□ OB/GYN	Rheumatology
□ Cardiology	Internal Me	d/Family Practice	□ Other	□ Surgery
□ Gastroenterology	Nephrology	,	Otolaryngology	□ Urology
	□ Neurology		□ Pulmonary	□ Wound Care

Appointment Requests

|

+

Confidentiality of this medical record shall be maintained except when use or disclosure is required or permitted by law, regulation, or written authorization by the patient. Infusion Appointment Request

Status: Future, Expected: S, Expires: S+365, Sched. Tolerance: Schedule appointment at most 3 days before or at most 3 days after, Injection and possible labs

Provider Ordering Guidelines

ONC PROVIDER REMINDER 10

- EPOETIN ALFA or EPOETIN ALFA-EPBX ORDERING GUIDELINES:
- Retacrit (epoetin alfa-epbx) is approved as a biosimilar to Epogen (epoetin alfa) and Procrit (epoetin alfa). Epoetin alfa-epbx (RETACRIT) is the preferred formulation at Spectrum Health.
- Doses are usually rounded to the nearest vial size.
- Evaluate iron status in all patients before and during treatment and maintain iron repletion.
- In patients with ANEMIA due to CHRONIC KIDNEY DISEASE (CKD), individualize dosing and use the lowest dose necessary to
 reduce the need for RBC transfusions.
- Do not increase dose more frequently than every 4 weeks (dose decreases may occur more frequently); avoid frequent dosage adjustments. Most patients with chronic kidney disease (CKD) will require iron supplementation.
- If Hemoglobin does not increase by GREATER THAN 1 g/dL after 4 weeks: Increase dose by 25%.
- If Hemoglobin increases GREATER THAN 1 g/dL in any 2-week period: Reduce dose by GREATER THAN OR EQUAL TO 25%.
- Inadequate or lack of response over a 12-week escalation period: Further increases are unlikely to improve response and may
 increase risks; use the minimum effective dose that will maintain a Hemoglobin level sufficient to avoid RBC transfusions and
 evaluate patient for other causes of anemia. Discontinue therapy if responsiveness does not improve.
- In patients with ANEMIA due to CHEMOTHERAPY IN CANCER PATIENTS, discontinue erythropoietin following completion of chemotherapy.
- If hemoglobin does not increase by GREATER THAN OR EQUAL TO 1 g/dL and remains less than 10 g/dL after initial 4 weeks: Increase to 900 units/kg (maximum dose: 60,000 units); discontinue after 8 weeks of treatment if RBC transfusions are still required or there is no hemoglobin response.
- If hemoglobin exceeds a level needed to avoid red blood cell transfusion: Withhold dose; resume treatment with a 25% dose reduction when hemoglobin approaches a level where transfusions may be required.
- If hemoglobin increases GREATER THAN 1 g/dL in any 2-week period or hemoglobin reaches a level sufficient to avoid red blood cell transfusion: Reduce dose by 25%.

CONTINUED ON PAGE 2 →

Spectrue Health

Spectrum EPOETIN ALFA Health (PROCRIT/RETACRIT) -ADULT, OUTPATIENT, INFUSION CENTER (CONTINUED) Page 2 to 2

FIN

Treatment Parameters

~

ONC MONITORING AND HOLD PARAMETERS 2

Hold medication and notify provider, if Hemoglobin is greater than 11 g/dL OR Hematocrit is greater than 30%.

Labs			
		Interval	Duration
\checkmark	Hemoglobin + Hematocrit (H+H)		
	Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Colle	ect, Blood, Blood, Venous	
\checkmark	Transferrin, Blood Level	Once	1 treatment
	Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Colle	ect, Blood, Blood, Venous	
\checkmark	Ferritin, Blood Level	Once	1 treatment
	Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Colle	ect, Blood, Blood, Venous	
✓	Iron and Iron Binding Capacity Level	Once	1 treatment
	Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Colle	ect, Blood, Blood, Venous	
✓	Erythropoietin (EPO), Serum	Once	1 treatment
	Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Colle	ect, Blood, Blood, Venous	
~	Reticulocyte Count with Reticulocyte Hemoglobin	Once	1 treatment
	Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Colle	ect, Blood, Blood, Venous	
	Labs:	□ Everydays	Until date:
		Once	🗆 1 year
			# of Treatments

Medications

Epoetin Alfa-epbx (Retacrit) Is the PREFERRED Formulary Product at Spectrum Health: Select Epoetin Alfa or Epoetin Alfa-epbx

 epoetin alfa-epbx (RETACRIT) injection (PREFERRED Formulary Product) Dose:
 40,000 units
 60,000 units

- □ 50 units/kg
- □ 100 units/kg

units OR units/kg

Indications:

- Anemia
- Chemotherapy-induced anemia
- ESRD on Dialysis
- □ Radiation Therapy Toxicity Subcutaneous, Once, Starting S, For 1 Dose

epoetin alfa (EPOGEN, PROCRIT) injection

- Dose: 40,000 units 60,000 units 50 units/kg 100 units/kgunits OR units/kg Indications: Anemia Chemotherapy-induced anemia ESRD on Dialysis
 - □Radiation Therapy Toxicity

Subcutaneous, Once, Starting S, For 1 Dose

Telephone order/Verbal order documented and read-back completed. Practitioner's initials

NOTE: Unless Order is written DAW (dispense as written), medication may be supplied which is a generic equivalent by nonproprietary name.

TRANSCRIBED:		VALIDATED:		ORDERED:			
TIME	DATE	TIME	DATE	ТІМЕ	DATE	Pager #	
	Sign		R.N. Sign		Physician Print	Physicia	n

+

+